| RA (n = 85) | Naive RA (n = 16) | RA before abatacept (n = 18) |
---|---|---|---|
Female sex, n (%) | 67 (79) | 10 (63) | 15 (83) |
Age, years | 58.9 (13.1) | 55.9 (12.2) | 62.7 (13.2) |
Disease duration, months | 139.4 (153.9) | 6.7 (8.3) | 187.5 (144.2) |
DAS28-CRP | 3.7 (1.5) | 4.1 (1.6) | 4.2 (1.3) |
DAS28-ESR | 4.4 (1.6) | 4.9 (1.6) | 4.9 (1.2) |
CDAI | 16.6 (12.1) | 21.6 (14.5) | 21.4 (11.7) |
Rheumatoid factor, % positive | 74 (87) | 15 (94) | 15 (83) |
Anti-CCP antibody, % positive | 72 (85) | 13 (81) | 18 (100) |
Levels of CRP, mg/dl | 1.81 (3.24) | 3.40 (5.30) | 1.54 (2.85) |
Treatment naive, n (%) | 16 (19) | 16 (100) | 0 (0) |
Treatment with MTX, n (%) | 41 (48) | 0 (0) | 10 (56) |
Treatment with biologics, n (%) | 19 (22) | 0 (0) | 5 (28) |
 TNF-α inhibitor | 8 (9) | 0 (0) | 3 (17) |
 Tocilizumab | 5 (6) | 0 (0) | 2 (11) |
 Abatacept | 6 (7) | 0 (0) | 0 (0) |